(Q57949374)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17822458%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

title

Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17822458%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

main subject

phase II clinical trial

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17822458%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

Baptiste Albouy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17822458%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Jean-Marc Tourani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17822458%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Patrick Allain

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17822458%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Frederic Staerman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17822458%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Pascal Eschwege

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17822458%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Christian Pfister

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17822458%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

1 October 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17822458%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17822458%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17822458%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17822458%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

770-774

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17822458%20AND%20SRC:MED&resulttype=core&format=json

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

New approaches in hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

Current indications for chemotherapy in prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

Management of the spectrum of hormone refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

COX-2 in cancer--a player that's defining the rules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: pilot study of an effective subtoxic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07095.X

10.1111/J.1464-410X.2007.07095.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17822458%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference